In AML, it has been indicated that the administration of HDAC inhibitor, namely valproic acid, prior to CAR-T cell therapy selectively upregulated the expression level of NKG2DL on low-level expressing AML cell lines and on primary AML blasts. Here, HDAC9 is linked to acute myeloid leukemia.